Clinical Trial Update: An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study assessing the efficacy and safety of siltuximab in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED